Human papillomaviruses (HPV) are the etiologic agents responsible for benign epithelial proliferative disorders including genital warts and are a contributory factor in the pathogenesis of cervical cancer (for reviews, see references 61 and 63) . The capacity of several HPV types to override growth control in mammalian cells was mapped to the E6 and E7 genes by genetic studies (17, 34, 50) . In cell clones derived from HPV type 18 (HPV-18)-positive cervical carcinoma cells (SW756 cells), in which E6 and E7 expression can be controlled by glucocorticoids, it was demonstrated that expression of these viral oncogenes is required for maintenance of neoplastic growth properties (57) . Transformation of rodent fibroblasts was frequently used as an experimental approach to study the biological functions of viral oncogenes. Like the E1A gene of adenovirus type 5 (20, 49) , E7 of HPV-16 is able to transform primary rodent fibroblasts, in cooperation with an activated ras gene (44) . 14/2 cells (7) offer the unique opportunity to analyze the specific contribution of HPV-16 E7 to transformation of primary cells in cooperation with ras, since these cells were derived from baby rat kidney cells by constitutive expression of EJ-ras, combined with inducible expression of E7. Activation of E7 gene expression is sufficient to trigger cell proliferation in quiescent 14/2 cells, providing evidence that E7 can directly interfere with cell cycle control (2) .
It was shown that conserved regions I and II (CRI and CRII) of adenovirus E1A, both of which are involved in cell transformation (32, 58) , share structural and functional homology with conserved domains 1 and 2 (cd1 and cd2) of HPV-16 E7, both of which contribute to the transforming potential of E7 (43, 44) . Both CRII of E1A and cd2 of E7 mediate binding of the respective viral oncoproteins to an overlapping set of cellular proteins, including the product of the retinoblastoma gene (pRB), p107, cyclin A, cyclin E, and cdk2 (13, 56 ; for a recent review, see reference 11), while interactions of cd1 with cellular proteins have not been described. cd2 mutants of E7 are inactive in ras cotransformation assays (3, 18, 23) and fail to induce cellular DNA synthesis in quiescent rodent fibroblasts (3) . On the other hand, it was reported that cd1 mutants can induce DNA synthesis and are still able to cooperate to some extent with ras in the transformation of primary cells, although their transforming potential is considerably reduced (3) . Disruption of cd1 impairs the ability of E7 to promote anchorage-independent growth of established rodent fibroblasts (3) . The biochemical processes involved in cell transformation by E7 are poorly understood. In view of the fact that adenovirus E1A has the ability to modulate expression of various cyclin genes in infected cells (4, 53) , it appears possible that deregulation of cyclin gene expression contributes to the transforming potential also in the case of HPV-16 E7.
In the absence of viral oncoproteins, progression through the cell cycle in mammalian cells is controlled by cyclins and cyclin-dependent kinases (cdks) (for a review, see reference 45) . Cyclin gene expression is tightly regulated in a phasespecific manner (51) . Cyclin D1, which is required for progression through G 0 /G 1 in fibroblasts (1, 47) , apparently provides a regulatory link between the exposure of cells to growth factors and the activation of the cell cycle in quiescent cells (31, 60) . Cyclin E is expressed in mid-G 1 and associates with cdk2 (24) ; cyclin E is rate-limiting for passage through G 1 (38, 48) . Cyclin A is first expressed at the G 1 /S transition; this protein is required for S phase and passage through G 2 (15, 42) . Cyclin B expression starts during S phase, and the complex of cyclin B and p34 cdc2 is the key regulator of mitosis (37) . The enzymatic activity of cyclin-cdk complexes is controlled by cdk inhibitors, including p21
Cip1/WAF-1 , p27 KIP1 , p16
INK4
, and p15 INK4B (for a review, see reference 21). Cyclin A is believed to participate in DNA replication (5, 10, 15) and may have a role in transcription control during S phase (25, 29) . Cyclin A gene expression is regulated essentially at the level of transcriptional initiation; the promoter of the human cyclin A gene is silent during G 1 and strongly induced as cells enter S phase (19) .
To understand how HPV-16 E7 can transform mammalian cells, we asked whether the viral oncoprotein can modulate the expression of cell cycle regulatory proteins. It is shown here that expression of wild-type E7 in established rodent fibroblasts (NIH 3T3 cells) leads to a deregulation of cyclin gene expression; high levels of cyclin E and cyclin A were detected in E7-expressing cells but not in control cells, in the absence of external growth factors. In contrast, E7 did not affect cyclin D1 gene expression. Expression of E7 also induced transcription from the cyclin A promoter via an E2F binding site in transient transfection experiments, indicating that promoter activation is involved in the observed changes in the level of cyclin A. However, activation of cyclin A transcription by E7 is indirect and requires the synthesis of an additional cellular gene product(s), as shown in 14/2 cells. In this system, E7-driven induction of cyclin E and cyclin A gene expression was accompanied by an increase in the associated kinase activities. Analysis of E7 mutants indicates that activation of cyclin E gene expression is dependent on cd2 but does not require cd1. On the other hand, activation of cyclin A gene expression depends on both cd1 and cd2 function. These data support a model in which the ability of E7 to induce cyclin E and cyclin A gene expression in the presence of antiproliferative signals is an essential step in growth promotion by E7; analysis of E7 mutants indicates that this property of E7 cosegregates with its ability to transform cells.
MATERIALS AND METHODS
Cell culture and synchronization. NIH 3T3 cells and transfected derivatives were propagated in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% bovine calf serum (CS).
NIH 3T3 cells were arrested in G 0 by culture in DMEM-0.5% CS for 48 h and were released into the cell cycle by the addition of CS to a final concentration of 10%.
The BRK cell line 14/2 (7) was grown in DMEM-10% fetal CS containing 1 M dexamethasone. 14/2 cells were synchronized by hormone withdrawal for 48 h, in the presence of 10% fetal CS. Cell proliferation was induced by readdition of 1 M dexamethasone. When indicated, cycloheximide was added to a final concentration of 50 g/ml. Cell cycle progression was monitored by fluorescenceactivated cell sorter (FACS) analysis, using a Becton Dickinson FACScan system and cell-fit program, and by [methyl-3 H]thymidine incorporation, as described elsewhere (12) . Whole-cell extracts were prepared by using RIPA buffer (20 mM Tris-HCl [pH 7.4], 100 mM NaCl, 0.5% Nonidet P-40, 0.5% sodium dodecyl sulfate, 0.5% deoxycholate, 0.5 mM phenylmethylsulfonyl fluoride, 0.2 mM Na 3 VO 4 , 0.1 g of aprotinin per ml, 0.02% mertiolate).
Western blot (immunoblot) analysis. Immunoblots were performed as described elsewhere (53) by using the enhanced chemiluminescence Western blotting detection system (Du Pont de Nemours). Cyclin A, cdk2, and cyclin D1 were Northern (RNA) blotting. Total cellular RNA was prepared by the guanidinium thiocyanate-acid phenol method. Samples (10 g) of total RNA were separated on formaldehyde agarose gels and transferred to Hybond N ϩ -membranes (Amersham) by capillary transfer.
Expression of cyclin A and cyclin E was monitored with murine probes, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression was analyzed by using a rat cDNA probe, as described elsewhere (22) . Cyclin D1 expression was detected with a mouse cyl1 probe (31) . A 340-bp EcoRI-HindIII E7-cDNA fragment was used for detection of HPV-16 E7 gene expression.
Plasmid constructs. E7 expression plasmids were described previously (8) . Details of the construction of human cyclin A promoter-luciferase reporter plasmids are described elsewhere (49a) .
Transfection experiments. NIH 3T3 cells were transfected by calcium phosphate precipitation as described elsewhere (6) . At 16 h postincubation, cells were washed and placed in DMEM containing 0.5% CS. Luciferase and ␤-galactosidase assays were performed on cell extracts prepared 36 h after transfection. Variations in transfection efficiency were accounted for by normalizing to a cotransfected cytomegalovirus promoter-driven ␤-galactosidase control plasmid.
Immunoprecipitation. A total of 10 7 cells were extracted in 1 ml of lysis buffer containing 50 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (HEPES; pH 7.0), 150 mM NaCl, 0.1% Nonidet P-40, 0.2 mM phenylmethylsulfonyl fluoride, 100 M sodium orthovanadate, 10 mM ␤-glycerophosphate, 1 mM NaF, and 10 g of aprotinin per ml for 30 min at 4ЊC. Cell lysates were centrifuged to remove cell debris, and supernatants were precleared for 1 h by using protein A-agarose (Santa Cruz Biotechnology, Inc.). Precleared lysates were then subjected to immunoprecipitation by using agarose-conjugated polyclonal antibody against cyclin E (M-20) or cyclin A.
Immunoprecipitates were washed three times with lysis buffer and twice with kinase buffer (50 mM Tris-HCl [pH 7.4], 10 mM MgCl 2 , 1 mM dithiothreitol).
Immunoprecipitates were resuspended in kinase buffer for histone H1 kinase assays.
In vitro kinase assays. Immunoprecipitates were supplemented with 5 g of histone H1 per ml, 1 M ATP, and 100 Ci of [␥-32 P]ATP per ml, and reaction mixtures were incubated 15 min at room temperature.
Reactions were terminated by the addition of 2ϫ sample buffer.
32
P-labelled proteins were resolved on a 10% polyacrylamide gel, visualized by autoradiography, and quantitated with a PhosphorImager (Molecular Dynamics, Inc.).
RESULTS
Growth factor-independent expression of the cyclin A gene depends on both cd1 and cd2, while cd2 is sufficient to trigger cyclin E gene expression. To investigate the potential of HPV-16 E7 to modulate cyclin gene expression, we analyzed the expression of different cyclins in NIH 3T3 cells, which had been engineered to express the viral oncogene from a retroviral vector (8) . E7-expressing (E7/4) and control (pMo) cells were kept for 48 h in DMEM containing 0.5% CS and subsequently refed by DMEM containing 10% CS. As expected, serum starvation led to G 1 arrest of the control cell population; in contrast, E7/4 cells display a substantial proportion of cells in S phase upon serum starvation (Fig. 1A) . The apparent proportion of cells in S phase was further increased by the addition of serum to E7/4 cells, indicating that the growth factor requirement of NIH 3T3 cells is reduced but not abolished by E7. Upon serum withdrawal, E7-expressing cells continued to incorporate [ 3 H]thymidine, although the level of incorporation was reduced about twofold ( Fig. 1B) , confirming that the cells fail to exit completely from DNA synthesis. Apparently, these cells are in a particular stage between quiescence and proliferation, most likely because of their exposure to antiproliferative signals in the presence of a growth-promoting viral gene. It is possible that this phenotype reflects partial activation of a proliferation program (see also below). Several different clones, expressing different quantities of E7, were used and gave essentially the same results (data not shown). To identify domains of E7 responsible for growth factor-independent S-phase entry, we analyzed cell cycle regulation of NIH 3T3-derived cell lines stably expressing cd1 (PRO 2) and cd2 (GLY 24) mutants of HPV-16 E7. The levels of mutant E7 proteins detectable in GLY 24 and PRO 2 cells are similar to the level of wild-type E7 expressed in E7/4 cells, as deduced from Western blotting experiments (8, 26) . Upon serum starvation, both PRO 2 and GLY 24 cell populations were accumulating in G 1 . At the level of resolution possible with FACS analysis, PRO 2 and GLY 24 cells could not be distinguished from control NIH 3T3 cells (Fig. 1A) , indicating that S-phase entry of serum-starved E7-expressing cells depends on both cd1 and cd2 domains of E7. However, we observed a residual incorporation of [ 3 H]thymidine in serum-starved PRO 2 cells, while in serum-starved GLY 24 cells [ 3 H]thymidine incorporation was reduced to background levels, as in control cells (Fig. 1B) .
To analyze whether the ability of E7-expressing cells to enter S phase in the absence of external growth factors correlates with altered regulation of cyclin gene expression, RNA was prepared from cells kept in the presence of 0.5 and 10% CS and analyzed by Northern blotting. The levels of cyclin E, cyclin A, and cyclin D1 mRNA were indistinguishable, when asynchronously growing E7-expressing (E7/4) and control (pMo) cells were compared ( Fig. 2A and B) . However, the levels of both cyclin E and cyclin A mRNA were only slightly down regulated by serum starvation in E7-expressing cells, whereas expression of both genes was severely reduced by serum starvation in control cells. On the other hand, mRNA levels for cyclin D1 were equally well reduced in serum-starved Fig. 2A) , indicating that expression of the cyclin D1 gene is not affected by E7 in these cells. To identify domains of E7 responsible for the activation of cyclin A and cyclin E gene expression, growth factor-independent expression of the cyclin A and cyclin E genes in PRO 2 and GLY 24 cells was analyzed. In serumstarved GLY 24 cells, no mRNA for cyclin E or cyclin A could be detected (Fig. 2A) . Mutation of cd1, as in mutant PRO 2, considerably reduced cyclin A mRNA, while expression of cyclin E mRNA in PRO 2 cells was comparable to that observed in cells expressing wild-type E7. Thus, the integrity of cd2 appears to be responsible for E7's ability to upregulate cyclin E gene expression, while efficient activation of cyclin A gene expression requires cd1 in addition to cd2 ( Fig. 2A) .
Protein extracts were prepared from parallel samples and analyzed by Western blotting. Similar to the results obtained with cyclin A mRNA, E7-expressing cells failed to down regulate cyclin A protein levels when serum was withdrawn ( Fig.  2C and D) . The failure of both PRO 2 and GLY 24 to promote growth factor-independent activation of the cyclin A gene was reflected by severely reduced levels of cyclin A protein. As was shown for cyclin D1 mRNA, the amount of cyclin D1 protein was equally well reduced in serum-starved cells, irrespective of the expression of E7 (Fig. 2C ). We were unable to detect a significant reduction of cyclin E protein levels upon serum starvation of control and E7-expressing cells (Fig. 2C) . Since we failed to detect any cyclin E mRNA in serum-starved control cells ( Fig. 2A) , this observation implies that a substantial amount of cyclin E, produced in the previous cell cycle, persists during the 48-h starvation period.
Transcriptional activation of the cyclin A gene promoter by E7. To test whether activation of the cyclin A promoter accounts for the observed increase of cyclin A mRNA in E7-expressing cells, we asked whether overexpression of E7 would lead to an increase in the activity of this promoter. NIH 3T3 cells were transiently transfected with expression plasmids for HPV-16 E7, together with reporter plasmids carrying the firefly luciferase cDNA linked to fragments of the human cyclin A gene promoter. Since the ability of E7 to induce the endogenous cyclin A gene in NIH 3T3 cells was detectable only in the absence of external mitogens (Fig. 2) , transfection experiments were performed under conditions where external growth factors were limiting (see Materials and Methods). Transcription from a reporter plasmid containing 7.5 kb of cyclin A 5Ј-flanking sequence (19) was stimulated 8-to 10-fold by cotransfection of an expression vector for HPV-16 E7 (Fig. 3A) . Activation of the cyclin A promoter could be further augmented by increasing the amount of transfected E7 expression vector (Fig. 3B) . To identify the region of the cyclin A promoter that is responsible for trans activation by E7, we used a series of 5Ј and 3Ј external promoter deletion mutants. By measuring changes in the promoter activity upon E7 overexpression, we established that responsiveness to E7 is retained in a 100-bp fragment, containing cyclin A promoter sequences between Ϫ89 and ϩ11. Further deletion of cyclin A promoter sequences, as in construct Ϫ32/ϩ11, completely abolished inducibility of the construct by E7 (Fig. 3A) . To identify the E7-responsive element(s) of the cyclin A gene, we used a series of promoter mutants based on the Ϫ89/ϩ11 minimal promoter. We had shown previously that there is a binding site for the transcription factor E2F, located at positions Ϫ33 to Ϫ37, which mediates cell cycle regulation of the cyclin A gene (49a). Using the reporter gene construct Ϫ89/ϩ11⌬E2F, in which the E2F binding site is abolished by clustered point mutations, we found that disruption of this binding site reduced responsiveness of the cyclin A promoter to E7 by about 50% (Fig. 3C) . Thus, this E2F binding site plays a critical role in activation of cyclin A transcription by E7. However, full E7-dependent trans activation apparently depends on additional elements in the minimal promoter, which remain unidentified. To investigate the role of different domains of HPV-16 E7 in the activation of cyclin A gene expression, NIH 3T3 cells were transfected by the cyclin A reporter gene construct and expression vectors for various E7 mutants (Fig. 3D) . All mutants disrupting cd2 (GLY 24, GLY 26, and ⌬21-35 [8] ) were incapable of activating the cyclin A promoter, indicating that this domain is critical for trans activation. On the other hand, the PRO 2 mutant retained the capacity to activate cyclin A transcription, although the fold induction was reduced by about 50%, indicating that cd1 contributes to full activation of cyclin A transcription. The results obtained by transient transfection experiments correlate with the cyclin A mRNA levels observed in NIH 3T3 cells stably expressing PRO 2 and GLY 24 (Fig. 2) , respectively.
Sequential activation of cyclin E and cyclin A gene expression by HPV-16 E7. To analyze the contribution of HPV-16 E7 to cell transformation, 14/2 cells had been derived from baby rat kidney cells by constitutive expression of EJ-ras combined with inducible expression of E7, resulting in a conditionally transformed phenotype (7). 14/2 cells are arrested in G 1 in the absence of hormone and progress to S phase with high synchrony upon addition of dexamethasone, which turns on expression of E7 (2) (Fig. 4A) . To further investigate biochemical changes that occur upon E7-dependent cell transformation, we analyzed the kinetics of cyclin gene activation in 14/2 cells, which were induced to proliferate by the addition of 1 M dexamethasone; progression into S phase was monitored by [ 3 H]thymidine incorporation studies (data not shown) and FACScan analyses. In agreement with previous results, Sphase entry was detectable 10 h after the addition of hormone (Table 1) (7). RNA was prepared at regular intervals after dexamethasone addition; expression of E7 and the cyclin E, cyclin D1, and cyclin A genes was monitored by Northern blotting. As expected, E7 mRNA was absent from untreated controls and was rapidly induced by the addition of dexamethasone. While a constant level of cyclin D1 mRNA was detectable throughout the experiment, cyclin E mRNA was first detected at 4 h, while cyclin A mRNA appeared between 4 and 12 h in this experiment ( Fig. 4A and B) . Thus, the appearance of cyclin A mRNA is delayed with respect to expression of the E7 gene.
To more precisely define the timing of cyclin A gene expression and relate it to E7 protein levels, additional time course experiments were performed, involving sample preparation every 60 min. E7 protein is first detected 2 h after hormone addition; cyclin A is undetectable in arrested cells; it can first be detected 7 h after hormone addition (Fig. 4C) . Reproducibly, a small amount of cyclin E is detectable in 14/2 cells arrested by hormone withdrawal, which apparently results from expression of the cyclin E gene during the previous cell cycle, since no cyclin E mRNA is found in arrested 14/2 cells (Fig. 4A ). While initially a slight reduction of cyclin E protein is observed during E7-dependent resumption of cell proliferation, at later time points cyclin E levels rise again, following the first appearance of cyclin E mRNA. Cyclin D1 was already present in cells kept without hormone and remained unchanged throughout the experiment (Fig. 4C) , which is consistent with the results obtained by analysis of cyclin D1 mRNA (Fig. 4A) .
The expression profile for E7 and cyclin A observed in the experiment shown in Fig. 4 suggests that activation of cyclin A gene expression by E7 may not be direct, since there is a lag period of several hours between the availability of E7 proteins and the first detection of cyclin A mRNA. To further address this point, we analyzed the ability of E7 to activate cyclin A gene expression in the presence of a protein synthesis inhibitor. 14/2 cells, which were arrested by hormone withdrawal, were induced to grow by the addition of dexamethasone. At different time points, cycloheximide was added to block synthesis of cellular proteins at particular stages of the E7-depen- Addition of cycloheximide at 8 h resulted in the appearance of cyclin A at a level similar to that observed at 8 h in untreated cells; however, the further increase of cyclin A, which was observed in the absence of cycloheximide, did not occur (Fig.  5A ). An increase in the level of cyclin E protein was first observed at 5 h after dexamethasone addition (Fig. 4C) ; in cells treated with cycloheximide at 4 h, de novo synthesis of cyclin E protein was not observed (Fig. 5A) . RNA was prepared from parallel samples and analyzed for cyclin E and cyclin A gene expression. When cycloheximide was added at 4 h after the addition of hormone, cyclin E mRNA was rapidly accumulated, while cyclin A mRNA was not detectable throughout this experiment (Fig. 5B) . Thus, cyclin A gene expression is not activated under these conditions, although the cells have accumulated a high level of E7 protein at 4 h (Fig. 4C) . When cycloheximide was added at 8 h after the addition of hormone, cyclin A mRNA was easily detected at 10 h. These findings strongly suggest that activation of cyclin A gene expression by E7 is indirect and requires the synthesis of an additional cellular gene product(s). Activation of cdks by E7. To investigate the potential of E7 to activate the kinases associated with cyclins E and A, we analyzed the level of histone H1 kinase, which is associated with both cyclins in 14/2 cells. Extracts were prepared from 14/2 cells, which had been synchronized by hormone withdrawal for 48 h and subsequent readdition of dexamethasone. As shown in Fig. 6A , some kinase activity is associated with cyclin E in extracts from arrested 14/2 cells. In extracts prepared after the addition of hormone, a continuous increase of cyclin E-associated kinase was observed. As deduced from the results presented in Fig. 4 , the initial increase of kinase activity results from activation of the kinase associated with the residual amount of cyclin E found in growth-arrested 14/2 cells; it clearly precedes the de novo synthesis of cyclin E, which starts about 5 h after hormone addition. The further increase of cyclin E-associated kinase, which is observed at later time points (Fig. 6A and data not shown) , most likely reflects the higher cyclin E levels resulting from E7-dependent activation of the cyclin E gene, which is consistent with the finding that the amount of coprecipitated cdk2 (Fig. 6B) closely paralleled the accumulation of de novo synthesized cyclin E (Fig. 4C) . In contrast, E7 did not affect the overall level of cdk2 gene expression as measured by direct immunoblotting (Fig. 6B) .
In hormone-depleted 14/2 cells, only background levels of cyclin A-associated kinase were detected, consistent with the very low expression of cyclin A in these cells. After addition of dexamethasone, we noted a strong increase of cyclin A-associated kinase, starting at 12 h and reaching a peak 16 h after the addition of dexamethasone ( Fig. 6C and D; data not shown). These data indicate that expression of E7 results in the appearance not only of cyclin A but also of its associated kinase, which is required for S-phase entry (41).
DISCUSSION
We have analyzed biochemical changes involved in the transformation of rodent cells by the E7 oncogene of HPV-16. Two experimental systems were applied. First, HPV-16 E7 was expressed in established rodent fibroblasts (NIH 3T3), which were used previously to analyze the transforming potential of single candidate genes, including HPV-16 E7 (3, 44, 55) . It is shown here that expression of E7 in NIH 3T3 cells leads to constitutive expression of the cyclin E and cyclin A genes in the absence of external growth factors, while expression of the cyclin D1 gene, encoding a major regulator of G 1 progression during serum stimulation, is not affected by E7. Second, dexamethasone-dependent activation of HPV-16 E7 gene expression in 14/2 cells (7) was used to study the contribution of HPV-16 E7 to the transformation of primary baby rat kidney cells in an experimental system reproducing the classical ras cotransformation assay pioneered by Land et al. (27) , except that expression of E7 can be regulated during the experiments shown here. E7-dependent resumption of cell growth in 14/2 cells led to sequential activation of cyclin E and cyclin A gene expression, which was followed by an activation of the associated kinases. Activation of cyclin A gene expression by E7 is indirect and requires the synthesis of additional cellular pro- tein(s). Cyclin D1 is already fully expressed in resting cells, which express ras but not E7. Two-step activation of cyclin gene expression by conserved domains 2 and 1 of HPV-16 E7. Activation of cyclin E gene expression in NIH 3T3 cells, in the absence of growth factors, is dependent on cd2 but does not require cd1 (Fig. 2) . Since cd2 mediates binding of E7 to proteins of the RB family (for a review, see reference 11), E7 may antagonize negative regulation of the cyclin E gene by pRB or a related protein. Functional analysis of the cyclin E gene promoter, which was recently isolated (3a), will be required to understand E7-dependent deregulation of the cyclin E gene. trans activation of the cyclin A promoter by E7 involves the E2F binding site of the cyclin A promoter (Fig. 3) . Since the E7 protein of HPV-16 binds with high affinity to pRB-related proteins, which are thought to control the activity of E2F, it was speculated that E7 may directly relieve negative control of E2F-driven genes by disrupting heteromeric complexes of E2F and pRB-related proteins (for reviews, see references 28 and 35). However, the requirement for additional protein synthesis (Fig. 5) is not easily reconciled with the hypothesis that physical interaction of E7 with preexisting E2F complexes on the cyclin A promoter triggers its activation. Furthermore, the ability of E7 to interact with pRB-related proteins by cd2, which apparently is sufficient to activate cyclin E gene expression in serum-starved PRO 2 cells, is not sufficient to induce expression of cyclin A transcription (Fig. 2) , revealing a distinct function for the transforming domain cd1 of the E7 oncoprotein, i.e., to cooperate with cd2 to trigger high-level cyclin A gene expression.
Although from the results shown in Fig. 5 it appears possible that cyclin E may be one of the intermediate cellular proteins that are required for induction of cyclin A gene expression by E7, the evidence for this interpretation is conflicting. It is shown here that serum starvation for 48 h is not sufficient to significantly reduce cyclin E protein levels in NIH 3T3 cells; however, under these conditions, expression of both the endogenous cyclin A gene (Fig. 2) and a transfected cyclin A promoter/reporter gene (49a) is inhibited. Cyclin A gene expression can be reactivated by serum addition, although the cyclin E protein levels are not significantly increased by serum growth factors under the conditions chosen here. It appears possible that similarly to the results obtained in serum-starved human fibroblasts (36) , the kinase activity associated with cyclin E is increased by addition of growth factors, because of inactivation of a kinase inhibitor, as, e.g., p27
KIP1 (36, 46) . Our finding that ectopic overexpression of cyclin E induces cyclin A promoter activity in serum-starved NIH 3T3 cells (60a) further suggests that cyclin A gene expression depends on the activation of cyclin E-associated kinase, possibly resulting from the titration of a cdk inhibitor, as proposed by Polyak et al. (46) . It is shown here that although expression of E7 in starved cells induces cyclin E mRNA, it does not lead to an increase in cyclin E protein levels; nevertheless, E7 induces cyclin A gene expression under these conditions.
These findings indicate that in the absence of E7, cyclin E must exceed a certain threshold level to overcome inhibition of the cyclin A promoter by serum starvation. In the absence of cyclin E overexpression, E7 can overcome starvation-mediated down regulation of cyclin A gene expression by an alternative pathway, potentially bypassing inhibition of cyclin E-associated kinase. Derepression of the cyclin A gene by E7 apparently involves both cd1 and cd2 function; the precise role of both domains in this process is currently under investigation.
The high level of cyclin D1 in growth-arrested 14/2 cells, which may result from expression of an activated ras gene (14) , is not reduced by E7. Similarly, the cyclin D1 levels in E7/4 cells and control cells are indistinguishable. These findings are at odds with the results described by Tam et al. (54) , who found that cyclin D1 gene expression was reduced in human keratinocytes expressing HPV-16 E7. While these conflicting results indicate that the capability of E7 to repress cyclin D1 gene expression may be determined by the genetic background of the target cell, our finding that cyclin D1 is reduced by simultaneous expression of both the E6 and E7 oncogenes of HPV18 (30) suggests that more than one oncogene product may be required for cyclin D1 repression. In support of this, we have recently shown that repression of cyclin D1 gene expression in adenovirus-infected diploid fibroblasts requires both the E1A and E1B oncogenes (52) , indicating that in addition to pRB (33) , p53, which is a cellular target for both adenovirus E1B and HPV-16 E6, contributes to expression of cyclin D1 in normal cells. However, more work is required to define the precise role of the HPV oncogenes for the regulation of cyclin D1 gene expression.
Correlation to cell transformation and viral oncogenesis. The data reported here support a model in which the ability of HPV-16 E7 to induce sequential activation of the cyclin E and cyclin A genes, which encode key regulators of the mammalian cell cycle (15, 38, 39, 42, 48, 59) , is critical for E7-dependent transformation of mammalian cells. While it appears possible that growth factor-independent expression of the cyclin A gene in E7/4 cells reflects the transformed phenotype of these cells, the constitutive synthesis of cyclin E mRNA in PRO 2 cells expressing a transformation-deficient mutant of E7 indicates that deregulation of cyclin E gene expression by E7 precedes cell transformation. Furthermore, the rapid induction of cyclin E gene expression in 14/2 cells suggests that this gene represents a bona fide target for E7. The alternate possibility, that E7-dependent cell transformation would involve the known capability of another G 1 cyclin, cyclin D1, to promote progression through G 1 (1, 47, 48) , is not compatible with our findings. The observation that E7-expressing NIH 3T3 cells can progress to S phase, even when cyclin D1 gene expression is drastically reduced by serum starvation (Fig. 1) , is in agreement with our previous observation that cyclin D1 is no longer required for cell cycle progression in cells expressing pRB-binding viral oncoproteins, including HPV-18 E7 (30) . In view of the results presented here, it may be speculated that E7 can replace some functions of cyclin D1, including the ability of cyclin D1 to activate the cyclin E (3a) and cyclin A (49a) gene promoters.
It was shown that cyclin A is critically involved in a checkpoint control mechanism which prevents S-phase entry of untransformed rodent fibroblasts, when cell adhesion is prevented (16) . The inability of the PRO 2 mutant to promote high levels of cyclin A gene expression, which is described in this report, correlates with the failure of PRO 2 to promote anchorage-independent growth of NIH 3T3 cells (3) . Furthermore, in an animal model for papillomavirus-associated disease, the formation of benign papillomas by cottontail rabbit papillomavirus (CRPV) requires the cd1 domain of the CRPV E7 oncoprotein (9) . These findings suggest that aberrant activation of cyclin A gene expression by cd1 contributes to the capacity of E7-expressing cells to grow under nonadherent conditions and plays a role in the formation of benign warts. In support of the latter possibility, it was shown that the CRPV E7 gene shares the ability to activate the human cyclin A promoter; moreover, a point mutation in cd1, which impairs the ability of E7 to induce benign warts (Leu-9 [9] ), considerably reduced the transactivation capability of CRPV E7 (60a).
Activation of cyclin A and cyclin E gene expression by E7 was observed only in growth-arrested cells (Fig. 2) , while expression of these genes is not elevated during the G 1 phase in proliferating E7-expressing cells, which had been synchronized by elutriation and nocodazole treatment, respectively (40; data not shown). Therefore, the results presented here allow conclusions only for the role of E7 to promote G 0 /G 1 progression in the presence of antiproliferative signals. These conditions may to some extent mimick the situation during viral infection, namely the induction of unscheduled DNA synthesis by HPV-16 in an environment which would restrict cell proliferation (for a review, see reference 62). While E7 apparently acts to overcome two separable control mechanisms, which restrict expression of the cyclin E and cyclin A genes in nontransformed rodent cells, it remains to be shown how these properties of the viral oncogene contribute to the deregulation of cellular growth control observed during HPV infection of human cells. As a matter of fact, growth factor-independent expression of the cyclin A gene has been observed in several HPV-16-positive cervical carcinoma cell lines (51a), indicating that deregulation of cyclin gene expression by HPV-16 E7 may play a role in HPV-associated cancer.
